Strong First Quarter Results for SciBase
In the recent interim report, SciBase has showcased an impressive performance for the first quarter of 2025. The medical technology company, renowned for its innovative dermatological solutions, recorded net sales of TSEK 8,856, marking a remarkable increase of 46% from the previous year’s figures.
Financial Performance Overview
The financial highlights for the first quarter provide a clear view of the company's growth trajectory. The loss after tax stood at TSEK 27,510, compared to TSEK 10,861 a year earlier. The loss per share remained steady at SEK 0.09. Despite the challenges, SciBase's gross margin showcased resilience, reaching 70.5%, while the cash flow from current operations was reported at a negative TSEK 26,001.
Sales Insights
The increase in electrode sales was a significant component of the overall sales performance, which surged by 30%, totaling 17,870 units sold. Moreover, repeat sales from existing customers increased by 20%, indicating growing trust and satisfaction in SciBase's products.
Market Growth and Strategy
Looking at the market distribution, sales in the skin cancer segment within Germany showed a commendable growth rate of 14%. However, it was the U.S. market that stole the spotlight, experiencing an astonishing 306% increase in sales. This remarkable growth trajectory reflects SciBase's successful strategy in penetrating new markets and solidifying its presence.
Key Events During the Quarter
Several important events during the quarter have marked SciBase's momentum:
- The company announced that the Mayo Clinic, a prominent U.S. healthcare institution, will conduct tests on its Nevisense product in a pilot program, which is an important step in establishing credibility and validation of their technology.
- SciBase disclosed details about its directed issue and rights issue, paving the way for future growth and development.
- Nevisense technology has received recognition in updated German imaging guidelines, underscoring its capabilities in detecting both Melanoma and Non-Melanoma skin cancers.
- Moreover, the company continues to onboard several U.S. dermatology practices, solidifying its role in skin cancer detection advancements.
Post-Quarter Developments
After the close of the quarter, SciBase announced the launch of the next generation of Nevisense, known as Nevisense V, which aims to further enhance its effectiveness and user experience, reinforcing the company’s commitment to innovation in dermatological technology.
Forward-Looking Statements and Future Growth
As SciBase continues to evolve, its focus remains on building partnerships with key healthcare providers and enhancing its product offering to better serve patients and clinicians alike. The ambition to minimize patient suffering while ensuring accurate and timely interventions is at the forefront of the company's mission.
The company strives for excellence in dermatology technology, enhancing diagnostic accuracy with the help of AI and advanced electrical impedance spectroscopy (EIS). This commitment to research and development has been nurtured through over two decades of collaboration with esteemed institutions like Karolinska Institute.
Company Information
SciBase is dedicated to early detection and prevention, offering pioneering solutions that help healthcare professionals manage skin health effectively. The company remains steadfast in its goal to empower clinicians in their pursuit of improved patient outcomes.
Contact for More Information: Michael Colérus, CFO, +46 70 341 34 72.
For additional inquiries: Pia Renaudin, CEO, tel. +46 732 069 802.
Frequently Asked Questions
What was the net sales figure for SciBase in Q1 2025?
The net sales for SciBase in Q1 2025 were TSEK 8,856.
How much did the loss after tax increase compared to last year?
The loss after tax increased from TSEK 10,861 to TSEK 27,510.
What percentage increase did the sales in the U.S. skin cancer market experience?
The sales in the U.S. skin cancer market increased by 306%.
What important recognition did the Nevisense technology receive?
Nevisense was included in the updated German imaging guidelines for detecting skin cancers.
Who can be contacted for more details about SciBase?
Michael Colérus, CFO, can be contacted at +46 70 341 34 72 for further details.
